New hope for CML patients: drug combo aims to control cancer after first treatment fails
NCT ID NCT07538401
First seen Apr 23, 2026 · Last updated May 15, 2026 · Updated 4 times
Summary
This study tests a new drug, asciminib, alone or with dasatinib, for people with chronic myeloid leukemia (CML) whose first treatment stopped working. About 45 adults will join this phase 2 trial to see if the drug can reduce cancer cells to very low levels after 24 weeks. The goal is to better control the disease, not cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA (CML) IN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.